Consolidation of responses to salvage chemo-radiotherapy regimens with high-dose therapy and autologous stem cell transplantation (ASCT) is a standard treatment strategy for transplant-eligible patients with relapsed aggressive or indolent B-cell and Hodgkin lymphomas.
The most commonly used conditioning regimen in Europe is BCNU, etoposide, cytarabine and melphalan (BEAM). This regimen is a variation on a previously used combination containing cyclophosphamide rather than melphalan, which in turn evolved from a lomustine-containing regimen that was developed in France. 1, 2 Lomustine was changed to BCNU partly due to concerns over its significant emetogenicity. Lomustine is widely available in Europe and used in both haematologic and solid malignancies. BCNU has been substituted due to concerns over toxicity (including pulmonary) with drugs such as Bendamustine or Fotemustine (an alternative chloroethylnitrosourea). [3] [4] [5] Primarily due to the restricted availability of BCNU and partly due to toxicity concerns, we have substituted BCNU with oral lomustine, using LEAM as our standard conditioning regimen since August 2008. There is very limited information available on the relative comparative toxicities (or efficacy) of the two regimens, and to address this deficit we undertook a retrospective analysis of two sequential comparable groups of patients.
Two cohorts of patients undergoing ASCT for relapsed/ refractory B-cell lymphoma were compared (50 patients per cohort), one conditioned with BEAM (BCNU 300 mg/m 2 , etoposide 800 mg/m 2 (in divided doses), cytarabine 1600 mg/m 2 (in divided doses) and melphalan140mg/m 2 , and the other with LEAM (lomustine 200 mg/m 2 instead of BCNU). Hospital records were used to identify the 50 most recent (consecutive) patients to have undergone ASCT with the relevant conditioning regimen. All histology was centrally reviewed.
Patients undergoing ASCT underwent at least daily assessments of symptoms by medical and nursing staff, and daily blood tests for routine biochemical and haematological parameters. Following discharge, patients were routinely reviewed 2 weeks and 3 months Eight LEAM patients were not evaluable for symptom analysis 2 weeks post discharge: six due to non-attendance at 2 weeks, two due to early deaths. Six BEAM patients were not evaluable for symptom analysis 2 weeks post discharge: Five due to non-attendance at 2 weeks, one due to early death. Nine LEAM patients were not evaluable for symptom analysis at 3 months due to: two early deaths and seven without appointments at the time. Eight BEAM patients were not evaluable due to one early death, and seven patients without an appointment at the relevant time.
after going home, before being transferred back to the referring centre. Toxicities were assessed retrospectively for each cohort, using the nursing and medical notes, according to CTCAEv4.0 criteria: nausea, vomiting, stomatitis and diarrhoea, alanine liver transaminase for hepatic toxicity and creatinine for renal toxicity. Surrogate markers for mucosal toxicity were also assessed, such as use of anti-diarrhoeals, opiates and syringe-driver anti-emetics. All toxicities reported during the ambulatory/inpatient phase and the two routine outpatient visits were included in this analysis.
Descriptive methods were used to calculate the mean and median. The unpaired t-test was used for continuous variables and Fisher's exact test for categorical values. Overall survival (OS) was defined as the time from the date of transplant to death from any cause. Progression-free survival (PFS) was defined as the date of transplant to the date of documented progression/relapse or death from any cause. Survival curves were estimated using the Kaplan-Meier method for OS and PFS, and cumulative incidence was estimated for non-relapse mortality (NRM) and relapse risk, with relapse as a competing risk for the NRM and death in remission for relapse risk. The log-rank test was used for comparison between different subgroups for PFS and OS, and Fine and Gray's method was used for NRM and relapse risk. P ⩽ 0.05 was considered significant.
The data set was locked and analysed in July 2015. There were no significant differences between the two cohorts in terms of patient demographics, indication for transplant, response to salvage chemotherapy or stem cell dose (Table 1) . Patients receiving LEAM did, however, have significantly better pretransplant renal function than those receiving BEAM (median glomerular filtration rate 108 versus 87, P = 0.03).
The median time to discharge from hospital was 23 days in both cohorts, and the choice of conditioning regimen did not affect the time to neutrophil and platelet engraftment. NRM and relapse rate are shown in Figure 1a . The NRM was similar in both cohorts: 4% for LEAM versus 2% for BEAM at 100 days, and 4% for both cohorts at 12 months; P = NS at both time points. NRM occurred in three patients in the LEAM cohort (at D+6 and D+8 from neutropenic sepsis, and 6.2 years from AML), and in two patients in the BEAM cohort (at D+7 from neutropenic sepsis, and 5 months from a respiratory tract infection). Relapse occurred in 12 patients in each cohort. The median time to relapse was 11.9 months in the LEAM cohort and 8.4 months in the BEAM cohort. There were no relapses after 3 years.
There was no significant difference in OS or PFS between the two cohorts (median 3-year OS and PFS were 86% and 69%, respectively for LEAM, and 86% and 75%, respectively for BEAM; Figures 1b and c) .
The toxicity associated with both conditioning regimens is shown in the Table 1 . The most common grades 3-4 toxicities observed in both cohorts were stomatitis (~30% in both cohorts), diarrhoea (~50% in both cohorts) and nausea (16% for LEAM and 6% for BEAM). Grades 3-4 hepatic and renal toxicity was infrequent in both cohorts (8% and 8%, respectively for LEAM, and 6% and 0%, respectively for BEAM, P = NS for both parameters). The median duration of diarrhoeal symptoms was similar for both conditioning regimens (12 days for LEAM versus 10.5 days for BEAM, P = NS). Overall, there was no statistically significant difference in any of the toxicity parameters measured between the two regimens before initial discharge from hospital. The proportion of patients reporting ongoing gastrointestinal symptoms following discharge was similar between the two cohorts 2 weeks post discharge (67% for LEAM versus 52% for BEAM, P = NS), but was significantly higher in the LEAM cohort than the BEAM cohort at 3 months post discharge (41% versus 14%, respectively, P = 0.001). This difference was due to an excess of diarrhoeal symptoms and abdominal pain in the LEAM cohort.
ASCT remains a standard treatment strategy for patients with chemosensitive relapsed lymphoma. With a better appreciation of the side effects of different conditioning regimens (for example, secondary malignancies with cyclophosphamide and TBI), and improvements in supportive care, the toxicity and risks associated with this approach have diminished. 6, 7 Nonetheless, there is no universally accepted gold-standard conditioning regimen, and significant potential risks persist.
The data presented represent the largest comparison of the LEAM and BEAM conditioning regimens. In well-balanced cohorts, there was no difference noted in NRM, PFS or OS. This finding of apparently equivalent efficacy is in keeping with recent published data from another single-institution study. 8 Both LEAM and BEAM were associated with significant gastrointestinal toxicity. There was, however, no difference in any toxicity parameter between the two regimens during the inpatient phase, or at 2 weeks post discharge. At the later time point (3 months post discharge), the LEAM regimen was associated with worse gastrointestinal toxicity compared with BEAM, but this is of doubtful clinical relevance, and reassuringly there was no difference in rates of sepsis, engraftment or other transplant-related parameters between the two cohorts. More patients conditioned with LEAM went to intensive care in the acute setting, but the difference was not significant and importantly, the non-relapse mortality was not statistically different between the two regimens.
The overall toxicity profile seen in our BEAM cohort is broadly similar to that reported in other series. [9] [10] [11] [12] There are fewer available data on LEAM toxicity. In a single institution study of 45 patients using this regimen, grades 2-3 mucositis occurred in 64.5%, grades 2-3 diarrhoea in 33% and grade 2 nausea and vomiting in 22%. Analysing our toxicity data together in a similar way shows comparable levels of mucositis (68%) and nausea/vomiting (44%), but significantly more diarrhoea (82%). 13 Only one small study has compared the relative toxicity of these two regimens, and interpretation is complicated by low patient numbers and imbalances in patient characteristics between the two cohorts. 8 We acknowledge that our study has limitations. Although toxicities were graded with CTCAE, this was done retrospectively using nursing and medical notes. It is, therefore, possible that documentation of side effects and toxicity differed over time, introducing a reporting bias that potentially accounted for the excess of late gastrointestinal toxicity observed in the (more recent) LEAM cohort. However, if this were the case, a generalized increase in toxicity in the LEAM cohort would be expected, which was not the case. Although the two cohorts were generally very well balanced, they were not exactly matched in time (seven BEAM transplants before 2008), which not only affects length of follow-up, but may also bias the types of supportive care available to manage the discussed toxicities.
In summary, LEAM and BEAM appear to be generally comparable conditioning regimens for autologous transplantation. We found no significant difference in survival outcomes, although analysis of larger registry cohorts would help to confirm this finding in a more robust manner.
